ECSP10010336A - Derivados de piridina - Google Patents

Derivados de piridina

Info

Publication number
ECSP10010336A
ECSP10010336A EC2010010336A ECSP10010336A ECSP10010336A EC SP10010336 A ECSP10010336 A EC SP10010336A EC 2010010336 A EC2010010336 A EC 2010010336A EC SP10010336 A ECSP10010336 A EC SP10010336A EC SP10010336 A ECSP10010336 A EC SP10010336A
Authority
EC
Ecuador
Prior art keywords
compounds
disorders
fibrosis
pulmonary
piridine derivatives
Prior art date
Application number
EC2010010336A
Other languages
English (en)
Inventor
Catherine Leblanc
Urs Baettig
Peter Alan Hunt
Nikolaus Johannes Stiefl
Robert Alexander Pulz
Claire Adcock
Maude Nadine Pierrette Pipet
Katrin Spiegel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP10010336A publication Critical patent/ECSP10010336A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula I, en forma libre o de sal o de solvato, en donde T1, T2, X, Ra, Rb, R8 y R9 tienen los significados que se indican en la descripción, y son útiles para el tratamiento de trastornos inflamatorios u obstructivos de las vías respiratorias, hipertensión pulmonar, fibrosis pulmonar, fibrosis hepática, enfermedades musculares y trastornos esqueléticos sistémicos. También se describen composiciones farmacéuticas que contienen los compuestos y procesos para prepararlos.
EC2010010336A 2008-01-11 2010-07-09 Derivados de piridina ECSP10010336A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08150187 2008-01-11
EP08168207 2008-11-03

Publications (1)

Publication Number Publication Date
ECSP10010336A true ECSP10010336A (es) 2010-08-31

Family

ID=40689319

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010336A ECSP10010336A (es) 2008-01-11 2010-07-09 Derivados de piridina

Country Status (22)

Country Link
US (1) US8343966B2 (es)
EP (1) EP2242742B1 (es)
JP (1) JP5566909B2 (es)
KR (1) KR20100101138A (es)
CN (1) CN101918362B (es)
AR (1) AR070519A1 (es)
AU (1) AU2009203681B2 (es)
BR (1) BRPI0907611A2 (es)
CA (1) CA2711803A1 (es)
CL (1) CL2009000029A1 (es)
CR (1) CR11490A (es)
EA (1) EA201001127A1 (es)
EC (1) ECSP10010336A (es)
ES (1) ES2562447T3 (es)
IL (1) IL206276A0 (es)
MA (1) MA31947B1 (es)
MX (1) MX2010007606A (es)
PE (1) PE20091316A1 (es)
TN (1) TN2010000255A1 (es)
TW (1) TW200938536A (es)
WO (1) WO2009087212A2 (es)
ZA (1) ZA201003929B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009263037B2 (en) * 2008-06-26 2011-10-06 Amgen Inc. Alkynyl alcohols as kinase inhibitors
PE20120325A1 (es) * 2009-05-19 2012-04-12 Dow Agrosciences Llc Aminopirimidinas sustituidas con arilo como agentes fungicidas
SG186871A1 (en) * 2010-07-05 2013-02-28 Merck Patent Gmbh Bipyridyl derivatives useful for the treatment of kinase - induced diseases
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
US20150284380A1 (en) 2012-10-31 2015-10-08 Bayer Cropscience Ag Novel heterocyclic compounds as pest control agents
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TN2016000270A1 (en) 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
AU2014391610B2 (en) 2014-04-24 2018-01-25 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
SG11201809559UA (en) 2016-06-13 2018-12-28 Glaxosmithkline Ip Dev Ltd Substituted pyridines as inhibitors of dnmt1
US11666555B2 (en) * 2017-05-17 2023-06-06 Drexel University RelA inhibitors for biofilm disruption
BR112020012651A2 (pt) * 2017-12-22 2020-12-01 Ravenna Pharmaceuticals, Inc. compostos derivados de aril-bipiridina amina como inibidores da fosfatidilinositol fosfato quinase, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos
TW201940165A (zh) 2018-01-29 2019-10-16 美商卡普勒斯療法有限責任公司 包含6員中心環的srebp抑制劑
EP4182322B1 (en) 2020-07-15 2024-04-24 Chiesi Farmaceutici S.p.A. Pyrido oxazine derivatives as alk5 inhibitors
EP4182323B1 (en) 2020-07-15 2024-04-24 Chiesi Farmaceutici S.p.A. Pyrido oxazine amino derivatives as alk5 inhibitors
PT4182308T (pt) 2020-07-15 2024-12-04 Chiesi Farm Spa Derivados de piridazinil amino como inibidores de alk5
WO2022136221A1 (en) 2020-12-23 2022-06-30 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
CN112707924A (zh) * 2020-12-26 2021-04-27 蚌埠中实化学技术有限公司 一种4-胺甲基苯硼酸盐酸盐的合成方法
CA3232178A1 (en) 2021-09-21 2023-03-30 Daniela PIZZIRANI Pyridazinyl amino derivatives as alk5 inhibitors
KR102556500B1 (ko) * 2021-11-19 2023-07-19 하나제약 주식회사 피롤 유도체 또는 이의 약학적 또는 식품학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 위장 질환의 예방, 개선 또는 치료용 조성물
US12319655B2 (en) 2021-12-09 2025-06-03 Deciphera Pharmaceuticals, Llc RAF kinase inhibitors and methods of use thereof
US20250270215A1 (en) 2022-04-27 2025-08-28 Chiesi Farmaceutici S.P.A. Imidazole derivatives as alk5 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909529A (en) * 1956-07-19 1959-10-20 Merck Ag E Process for preparing 3, 4-dihydro-1, 2-pyrano-(3, 4-c)-pyridone-(6)
BE789099A (fr) * 1971-09-22 1973-03-21 Boehringer Sohn Ingelheim Nouveaux derives de la pyridine et procede pour les fabriquer
JP4272338B2 (ja) * 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
EP1539748A1 (en) 2002-07-31 2005-06-15 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
US20040142978A1 (en) * 2002-12-12 2004-07-22 Pharmacia Corporation Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
MY145822A (en) 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
MX2008013430A (es) 2006-04-19 2009-01-26 Novartis Vaccines & Diagnostic Compuestos de indazol y metodos para la inhibición de cdc7.
CA2647338A1 (en) 2006-04-28 2007-11-08 Avexa Limited Integrase inhibitors-3
WO2007124544A1 (en) 2006-04-28 2007-11-08 Avexa Limited Integrase inhibitors - 1
WO2007124545A1 (en) 2006-04-28 2007-11-08 Avexa Limited Integrase inhibitors - 2
DK2125797T3 (da) 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
WO2008122378A1 (en) * 2007-04-04 2008-10-16 Ucb Pharma, S.A. Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof
JP2010525047A (ja) 2007-04-27 2010-07-22 アストラゼネカ アクチボラグ 増殖状態の処置のためのＥｐｈＢ４キナーゼ阻害剤としてのＮ’−（フェニル）−Ｎ−（モルホリン−４−イル−ピリジン−２−イル）−ピリミジン−２，４−ジアミン誘導体
EA201000615A1 (ru) * 2007-10-17 2010-12-30 Новартис Аг Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)

Also Published As

Publication number Publication date
KR20100101138A (ko) 2010-09-16
US20090215776A1 (en) 2009-08-27
AU2009203681A1 (en) 2009-07-16
CN101918362B (zh) 2013-11-27
WO2009087212A2 (en) 2009-07-16
JP5566909B2 (ja) 2014-08-06
US8343966B2 (en) 2013-01-01
AU2009203681B2 (en) 2012-08-16
ZA201003929B (en) 2011-03-30
TW200938536A (en) 2009-09-16
BRPI0907611A2 (pt) 2015-07-21
CN101918362A (zh) 2010-12-15
ES2562447T3 (es) 2016-03-04
EP2242742B1 (en) 2015-12-02
JP2011509277A (ja) 2011-03-24
CL2009000029A1 (es) 2009-07-24
AR070519A1 (es) 2010-04-14
WO2009087212A3 (en) 2009-09-24
EA201001127A1 (ru) 2011-02-28
TN2010000255A1 (en) 2011-11-11
MX2010007606A (es) 2010-08-23
IL206276A0 (en) 2010-12-30
CR11490A (es) 2010-08-11
EP2242742A2 (en) 2010-10-27
MA31947B1 (fr) 2010-12-01
CA2711803A1 (en) 2009-07-16
PE20091316A1 (es) 2009-09-24

Similar Documents

Publication Publication Date Title
CR11490A (es) Derivados de Piridina
CO6270321A2 (es) Derivados de imidazo[1,2-a]-piridina utiles como inhibidores de cinasa tipo activina (alk)
ECSP088082A (es) Derivados de piridazina
EA201001129A1 (ru) Пиримидины в качестве ингибиторов киназы
CY1124219T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν τοπικο αναiσθητiκο οπως η βουπιβακαϊνη για τοπικη χορηγηση στο στομα ή τον φαρυγγα
CO6310968A2 (es) Derivados de 3,5-diamino sustituido-n-tetrahidropirimidin/imidazolin/diazepam-2-ilidenpirazin-2-carboxamida, utiles como bloqueadores de la actividad del canal de sodio epitelial (enac)
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
CY1118909T1 (el) Αμιδια οξαλικου οξεος ως αναστολεις νεπριλυσινης, φαρμακευτικη συνθεση αυτων και παρασκευη αυτων
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
BRPI0908292A2 (pt) "métodos e composições para administração oral de exenatida"
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
CR20180086A (es) Tricíclicos sustituidos y métodos para usarlos
ATE517882T1 (de) Chinolinderivate
CO6290683A2 (es) Compuestos de pirido imidazolinas heterociclicas y sus composiciones como inhibidores de c-met
ECSP10010265A (es) Sales farmaceuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8 dihidro-9h-purin-9-il)propil](3-morfolin-4 ilpropil)amino]metil}fenil)
CR9703A (es) Derivados de pirazolona
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
MX380619B (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
CY1112255T1 (el) Ενωσεις οι οποιες περιεχουν γουανιδινη που ειναι χρησιμες ως ανταγωνιστες του μουσκαρινικου υποδοχεα
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
AR063027A1 (es) Derivados de sulfonamida
GT200500281A (es) Compuestos organicos.